Supplementary File

Table S1. SBRT dosimetric constraints

Structure	Constraint	Minor Variation	Major Variation
Bowel	V30 < 1 cc		
Rectum	V36 < 1 cc	V36 Gy ≥ 1 cc but < 2 cc	V36 Gy ≥ 2 cc
Bladder	V37 < 10 cc	V37 Gy ≥ 10 cc, but < 20 cc	V37 Gy ≥ 20 cc
PTV	Prescribed dose to > 95% of PTV	Prescribed dose to < 95% but > 90% of PTV	< 90% of PTV

Table S2. All GI and GU adverse events

Case	Baseline	Post-SBRT (0–1 month)	Post-RP (0–1 month)	Post-RP (2–5 months)	Post-RP (> 6 months)
1	None	G1 cystitis	G2 erectile dysfunction	G1 erectile dysfunction, G1 urinary incontinence	None
2	None	G1 cystitis	G2 bladder anastamotic leak, G2 hemorrhoidal bleed	G1 urinary incontinence	G1 urinary incontinence
3	None	None	G2 urinary incontinence, G2 erectile dysfunction	G3 urinary incontinence	G2 erectile dysfunction
4	G1 nocturia	G1 erectile dysfunction, G1 urinary frequency	G2 bladder anastamotic leak	G2 urinary incontinence	None
5	None	G1 urinary urgency	G2 urinary incontinence, G2 erectile dysfunction, G2 hematuria, G1 cystitis	G2 urinary incontinence, G2 erectile dysfunction	G2 urinary incontinence, G2 erectile dysfunction
6	G1 nocturia	G2 erectile dysfunction	G2 erectile dysfunction, G1 hemorrhoidal bleed	G2 erectile dysfunction	G2 erectile dysfunction
7	G1 nocturia	None	G1 hematuria	G2 urinary incontinence, G1 erectile dysfunction	G2 urinary incontinence, G2 erectile dysfunction